Departments of Radiopharmaceutical Cancer Research
- Radiotracer and Drug Development
- Theranostic Targets and Experimental Models
- Radiopharmacology and Cancer Imaging
- Tissue Regeneration and Inflammation Imaging
- Improved quantification of functional information in oncological PET
- Quantitative perfusion imaging using functional ASL-MRI
- Multimodal imaging and assessment of in vivo quantification accuracy
- Motion compensation methods for PET
- High resolution PET image reconstruction
- Small molecule and peptide-based radiotracer for PET-imaging of TME receptors
- Radiolabeled near-infrared (NIR) fluorescence dyes for optical and radio imaging
- Combination with theranostic approaches (e.g. endoradiotherapy and radioimmunotherapy)
- Generation of radioisotopes with cyclotron TR-Flex
- GMP-certified radiopharmaceuticals production and quality control
- Radioisotopes and radiotracer for preclinical application
Neuroradiopharmaceuticals, Prof. Dr. Klaus Kopka/Prof. Dr. Michael Bachmann (provisional)
- Molecular imaging of adenosine signalling in cancer
- Molecular imaging of α7 nAChR in cancer and brain diseases
- [18F]Flubatine - a potential PET marker of early Alzheimer`s disease
- Development of new ligands and 18F-radiotracers for the vesicular acetylcholine transporter (VAChT) in brain
- New PET Radioligands for Imaging of Cannabinoid Receptors Type 2 (CB2) in the Human Brain
- Radioligands for PET Imaging of Cyclic Nucleotide Phosphodiesterases 2A, 5A and 10A
- Development of 18F-labelled PET radiotracers for the imaging of σ receptors in cancer and brain diseases
×